CRAC channel inhibition therapies

Search documents
CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
Prnewswire· 2025-07-08 11:00
About CalciMedica CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead p ...